Academic Journal
Outcomes after allogeneic hematopoietic stem cell transplantation for adults with primary mediastinal B cell lymphoma: a SFGM-TC and LYSA study.
| العنوان: | Outcomes after allogeneic hematopoietic stem cell transplantation for adults with primary mediastinal B cell lymphoma: a SFGM-TC and LYSA study. |
|---|---|
| المؤلفون: | Le Calvez, Baptiste, Tessoullin, Benoit, Renaud, Loïc, Botella-Garcia, Carmen, Srour, Micha, Le Gouill, Steven, Guillerm, Gaelle, Gressin, Rémy, Nguyen Quoc, Stéphanie, Furst, Sabine, Chauchet, Adrien, Sibon, David, Lewalle, Philippe, Poiré, Xavier, Maillard, Natacha, Villate, Alban, Loschi, Michael, Paillassa, Jérôme, Beguin, Yves, Dulery, Rémy, Tudesq, Jean-Jacques, Fayard, Amandine, Béné, Marie C, Camus, Vincent, Chevallier, Patrice, Le Bourgeois, Amandine |
| المصدر: | Acta Oncologica, 61, 1332 - 1338 (2022) |
| بيانات النشر: | Taylor and Francis Ltd. |
| سنة النشر: | 2022 |
| المجموعة: | University of Liège: ORBi (Open Repository and Bibliography) |
| مصطلحات موضوعية: | Allogeneic stem cell transplantation, lymphoma, non Hodgkin lymphoma, primary mediastinal B cell lymphoma, Adult, Humans, Retrospective Studies, Remission Induction, Recurrence, Hematopoietic Stem Cell Transplantation/adverse effects, Graft vs Host Disease/etiology, B-Cell/therapy, B-Cell/complications, Hematology, Oncology, Radiology, Nuclear Medicine and Imaging, General Medicine, Human health sciences, Sciences de la santé humaine, Hématologie |
| الوصف: | peer reviewed ; Background: Despite therapeutic progress, 10 to 30% of adult patients with primary mediastinal B cell lymphoma (PMBCL) are primary refractory or experience early relapse (R/R). Allogeneic stem cell transplantation (allo-HSCT) thus remains a potentially curative option in this setting.Material and Methods: In this multicenter retrospective study, the outcomes of 33 French and Belgian adult patients allo-transplanted for R/R PMBCL between January 1999 and December 2018, were examined.Results: At allo-HSCT time, patients had received a median of 3 treatment lines, 50% of them were in complete response, 40% in partial response and 10% had a progressive disease. Forty-two percent of the donors were siblings and 39% matched related. The median follow-up for alive patients was 78 months (3.5-157). Considering the whole cohort, 2-year overall survival (OS), progression free survival (PFS) and graft-versus-host disease-free/relapse-free survival (GRFS) were 48% (95%CI: 33-70), 47% (95%CI: 33-68) and 38.5% (95%CI: 25-60) respectively. Cumulative incidence of relapse and non-relapse mortality rates were respectively 34% (95%CI: 18-50) and 18% (95%CI: 7-34). Disease status at transplant was the only factor predicting survivals, patients with progressive disease showing significant lower 2-year PFS (HR: 6.12, 95%CI: 1.32-28.31, p = 0.02) and OS (HR: 7.04, 95%CI: 1.52-32.75, p = 0.013). A plateau was observed for OS and PFS after 4 years with 10 patients alive after this date, suggesting that almost one third of the patients effectively salvaged and undergoing allo-SCT could be cured.Conclusion: This study indicates that allo-HSCT is a valid therapeutic option for R/R PMBCL, providing durable remissions. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| تدمد: | 0284-186X 1651-226X |
| Relation: | urn:issn:0284-186X; urn:issn:1651-226X; https://orbi.uliege.be/handle/2268/297868; info:hdl:2268/297868; https://orbi.uliege.be/bitstream/2268/297868/1/489.pdf; info:pmid:36214787 |
| DOI: | 10.1080/0284186X.2022.2130709 |
| الاتاحة: | https://orbi.uliege.be/handle/2268/297868 https://orbi.uliege.be/bitstream/2268/297868/1/489.pdf https://doi.org/10.1080/0284186X.2022.2130709 |
| Rights: | open access ; http://purl.org/coar/access_right/c_abf2 ; info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.2B105348 |
| قاعدة البيانات: | BASE |
| تدمد: | 0284186X 1651226X |
|---|---|
| DOI: | 10.1080/0284186X.2022.2130709 |